Bruker CORP 8-K filings

Bruker Corporation announced second quarter 2026 financial results, showing a return to organic revenue growth and strong bookings, alongside a significant goodwill impairment charge impacting GAAP results.

Bruker Corporation announced its Board of Directors has declared a quarterly cash dividend for its 6.375% Mandatory Convertible Preferred Stock, Series A.

Bruker Corporation confirms the election of directors and approval of executive compensation at its 2026 Annual Meeting.

Bruker Corporation's 2026 Annual Meeting saw the election of Class II directors, approval of executive compensation, and ratification of its independent auditor.

Bruker Corporation announced first quarter 2026 financial results, with revenues of $823.4 million, and reaffirmed its full-year 2026 financial outlook.

Bruker Corporation announced its Board of Directors has declared a quarterly cash dividend for its Series A Mandatory Convertible Preferred Stock.

Bruker Corporation announces executive officer Falko Busse's transition from his roles and subsequent departure, with a separation agreement detailing severance benefits.

Bruker Corporation announced the appointment of Thierry L. Bernard, current CEO of QIAGEN N.V., to its Board of Directors, effective April 1, 2026.

Bruker Corporation reported Q4-25 revenues ahead of expectations and a challenging FY25, while initiating strong FY26 guidance with double-digit non-GAAP EPS growth.

Bruker Corporation announced preliminary fourth-quarter 2025 revenue expectations between $965 million and $970 million and projected double-digit non-GAAP EPS growth for full-year 2026.

Bruker Corporation announced the appointment of Jack J. Phillips, a seasoned diagnostics industry executive, to its Board of Directors, effective January 1, 2026.

Bruker Corporation reported a slight revenue decrease and a GAAP loss in Q3 2025, leading to a revised downward full-year 2025 financial outlook, despite better-than-expected non-GAAP performance.

Bruker Corporation completed an underwritten public offering of 2.76 million shares of 6.375% Mandatory Convertible Preferred Stock, Series A, raising approximately $669.5 million in net proceeds.

Bruker Corporation reported second quarter 2025 financial results below expectations, leading to a revised downward full-year 2025 financial outlook.

Bruker Corporation announced preliminary second quarter 2025 results, projecting flat reported revenue year-over-year but a significant decline in non-GAAP organic revenue and a substantial drop in non-GAAP EPS.

Bruker Corporation's stockholders approved the new 2026 Incentive Compensation Plan, re-elected Class I directors, and ratified the independent auditor at the 2025 Annual Meeting held on May 29, 2025.

Bruker Corporation and 10x Genomics have reached a global settlement to resolve their patent disputes, dismissing all ongoing lawsuits and administrative proceedings.

Bruker Corporation announced an 11.0% year-over-year revenue increase for Q1 2025, but lowered its full-year organic revenue growth and non-GAAP EPS guidance due to academic market and tariff dynamics.

Bruker Corporation reports preliminary Q1 2025 revenue between $795 million and $800 million, surpassing previous outlook and consensus estimates.

Bruker Corporation has appointed Laura Francis, CEO of SI-BONE, Inc., to its Board of Directors, effective February 18, 2025.

Bruker Corporation announces a 14.6% year-over-year revenue increase for Q4 2024 and initiates FY 2025 guidance with expected revenue growth of 3% to 5% and non-GAAP EPS growth of 11% to 13%.

Bruker Corporation has appointed Thomas Bures as its new Chief Accounting Officer, effective immediately, with a base salary of $415,000.04 and a significant stock grant.

Bruker Corporation anticipates Q4 2024 revenue between $970 million and $980 million and projects upper mid-single digit revenue growth for 2025 at constant exchange rates.

Bruker Corporation reported a 16.4% year-over-year revenue increase for Q3 2024, but lowered its full-year guidance due to biopharma and China recovery delays.

Bruker Corporation reports the immediate resignation of board member Dr. Philip Ma, effective August 5, 2024, to focus on his own company.

Bruker Corporation announced a 17.4% year-over-year revenue increase for Q2 2024, driven by organic growth and strategic acquisitions, and raised its full-year revenue guidance.

Bruker Corporation filed an amended 8-K report to correct a clerical error regarding the number of shares issued in a recent public offering.

Bruker Corporation has launched a public offering of 6 million shares of its common stock, with an option for underwriters to purchase an additional 900,000 shares.

Bruker Corporation adopted amended and restated bylaws and held its 2024 annual meeting of stockholders, with key changes including enhanced notice procedures for director nominations and a forum selection clause.

Bruker Corporation reported a 5.3% year-over-year revenue increase in the first quarter of 2024, driven by acquisitions and solid organic growth, leading to an updated and increased full-year revenue and EPS guidance.